Kiniksa Pharmaceuticals International Plc (KNSA) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$78.78

From 52W high−1.78%

Volume594953.00

Market cap$6.20B

P/E (TTM)74.3x

P/S (TTM)7.4x

Div yield—

Key dataOct 19, 2026

Open

$78.78

From 52W high

−1.78%

Volume

594953.00

Market cap

$6.20B

ValuationView details →

P/E (Fwd)

45.4x

EV/EBITDA

50.7x

P/E (TTM)

74.3x

RSI (14)

57.6

MomentumView details →

1D Return

+1.13%

YTD Return

+92.85%

SummaryUpdated Jun 1, 2026

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is a biopharmaceutical company founded in 2015 and based in Hamilton, Bermuda. The company went public in May 2018 and focuses on developing and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. Kiniksa has successfully transitioned from a development-stage company to a profitable commercial enterprise, primarily driven by the success of its flagship product ARCALYST for treating recurrent pericarditis, a rare inflammatory cardiovascular condition.

Ask drillr about Kiniksa Pharmaceuticals International Plc →

ValuationView details →

P/E (Fwd)

45.4x

P/E (TTM)

74.3x

EV/EBITDA

50.7x

EV/Sales

6.8x

P/S (TTM)

7.4x

P/B (TTM)

9.5x

ProfitabilityView details →

Gross Margin

54.49%

Net Margin

9.59%

EBITDA Margin

13.33%

ROE (TTM)

12.33%

ROA (TTM)

9.00%

Asset Turnover

0.98x

GrowthView details →

Revenue YoY

+58.85%

EPS YoY

+1683.33%

FCF YoY

+175.38%

Revenue CAGR 3Y

+45.45%

EPS CAGR 3Y

−32.83%

EBITDA YoY

+742.35%

MomentumView details →

1D Return

+1.13%

YTD Return

+92.85%

1Y Return

+104.03%

RSI (14)

57.6

vs 50D SMA

+2.11%

vs 200D SMA

+36.62%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

3.90x

Quick Ratio

3.49x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.30

EPS Surprise

0.17%

Beats (12Q)

8/12

Next Q EPS Est

$0.36

Avg Surprise (4Q)

−5.38%

Rev Surprise

7.56%

Financials snapshotView financials →

Revenue (TTM)

840.85M

Net Income (TTM)

80.66M

Op. CF (TTM)

185.23M

Next earningsOct 27, 2026 →

Latest newsMore news →

Kiniksa Pharmaceuticals International, plc reported Q2 2026 earnings of $0.3 per share, matching the Zacks Consensus Estimate and up from $0.23 per share a year ago.83d ago

Similar companies

Lepu Biopharma Co., Ltd.02157.HK Centessa Pharmaceuticals plcCNTA Terns Pharmaceuticals, Inc.TERN Rhythm Pharmaceuticals, Inc.RYTM 科前生物688526.SH Iovance Biotherapeutics, Inc.IOVA Find similar companies →

Latest newsMore news →

Kiniksa Pharmaceuticals International, plc reported Q2 2026 earnings of $0.3 per share, matching the Zacks Consensus Estimate and up from $0.23 per share a year ago.83d ago